FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2359630417> ?p ?o ?g. }

• W2359630417 endingPage "18" @default.
• W2359630417 startingPage "18" @default.
• W2359630417 abstract "18 Background: Enzalutamide (ENZA) is an oral androgen receptor inhibitor that has been approved in the US and shown to increase overall survival by 4.8 months over a placebo (HR, 0.63) in patients with metastatic castration resistant prostate cancer (CRPC) previously treated with docetaxel (Scher et al, N Engl J Med 2012;367:1187). Compared with bicalutamide in nonclinical studies, enzalutamide had higher androgen receptor–binding affinity, prevented nuclear translocation, showed no DNA binding, and induced apoptosis (Tran et al, Science 2009;324:787). In contrast to previous phase II and III studies that exclusively enrolled patients with CRPC receiving androgen deprivation therapy (ie, testosterone (T) levels ≤50 ng/dL), this phase II study assessed the efficacy and safety of ENZA monotherapy in patients who had never received hormone therapy; presenting with non-castrate T levels (≥230 ng/dL). Methods: This was a 25-wk, open-label, single-arm study of patients with hormone-naïve, histologically confirmed prostate cancer (all stages) requiring hormonal treatment, an ECOG PS score of 0, and a life expectancy >1 y. All patients received ENZA 160 mg/d without concomitment castration. Primary endpoint was PSA response (>80% decrease at wk 25). Secondary endpoints included changes in endocrine levels and safety/tolerability. Results: Among 67 men enrolled, the median (range) age was 73 (48, 86) y; 39% had metastases; 36% and 24% had undergone prostatectomy or radiotherapy before study entry. The PSA response rate (>80% PSA decline at wk 25) was 93%, with a median (range) decrease of −99% (−100, −57) at wk 25. Serum T and estrogen levels increased by a median (range) of 113% (−32, 300) and 58% (−49, 321) at wk 25, respectively, compared with baseline. 82% of men reported drug-related AEs (mostly Grade 1 or 2). Most frequent treatment-emergent AEs included gynaecomastia (36%), fatigue (34%), and hot flush (18%). 7% of men experienced SAEs; none were drug-related. Conclusions: ENZA monotherapy (160 mg) was associated with significant PSA response in nearly all men with hormone-naïve prostate cancer. Endocrine level changes and most common AEs (gynecomastica, fatigue and hot flush) were consistent with potent AR inhibition. Clinical trial information: NCT01302041." @default.
• W2359630417 created "2016-06-24" @default.
• W2359630417 creator A5017925159 @default.
• W2359630417 creator A5020692060 @default.
• W2359630417 creator A5028709604 @default.
• W2359630417 creator A5031897059 @default.
• W2359630417 creator A5041545551 @default.
• W2359630417 creator A5047439092 @default.
• W2359630417 creator A5048118430 @default.
• W2359630417 creator A5070573139 @default.
• W2359630417 creator A5078094643 @default.
• W2359630417 creator A5078934527 @default.
• W2359630417 date "2013-02-20" @default.
• W2359630417 modified "2023-09-27" @default.
• W2359630417 title "Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer." @default.
• W2359630417 doi "https://doi.org/10.1200/jco.2013.31.6_suppl.18" @default.
• W2359630417 hasPublicationYear "2013" @default.
• W2359630417 type Work @default.
• W2359630417 sameAs 2359630417 @default.
• W2359630417 citedByCount "5" @default.
• W2359630417 countsByYear W23596304172013 @default.
• W2359630417 countsByYear W23596304172014 @default.
• W2359630417 countsByYear W23596304172020 @default.
• W2359630417 crossrefType "journal-article" @default.
• W2359630417 hasAuthorship W2359630417A5017925159 @default.
• W2359630417 hasAuthorship W2359630417A5020692060 @default.
• W2359630417 hasAuthorship W2359630417A5028709604 @default.
• W2359630417 hasAuthorship W2359630417A5031897059 @default.
• W2359630417 hasAuthorship W2359630417A5041545551 @default.
• W2359630417 hasAuthorship W2359630417A5047439092 @default.
• W2359630417 hasAuthorship W2359630417A5048118430 @default.
• W2359630417 hasAuthorship W2359630417A5070573139 @default.
• W2359630417 hasAuthorship W2359630417A5078094643 @default.
• W2359630417 hasAuthorship W2359630417A5078934527 @default.
• W2359630417 hasConcept C121608353 @default.
• W2359630417 hasConcept C126322002 @default.
• W2359630417 hasConcept C126894567 @default.
• W2359630417 hasConcept C142724271 @default.
• W2359630417 hasConcept C143998085 @default.
• W2359630417 hasConcept C197934379 @default.
• W2359630417 hasConcept C203092338 @default.
• W2359630417 hasConcept C204787440 @default.
• W2359630417 hasConcept C27081682 @default.
• W2359630417 hasConcept C2776551883 @default.
• W2359630417 hasConcept C2777899217 @default.
• W2359630417 hasConcept C2778375690 @default.
• W2359630417 hasConcept C2778575703 @default.
• W2359630417 hasConcept C2778894405 @default.
• W2359630417 hasConcept C2779279991 @default.
• W2359630417 hasConcept C2779448150 @default.
• W2359630417 hasConcept C2780192828 @default.
• W2359630417 hasConcept C2780962315 @default.
• W2359630417 hasConcept C2781190966 @default.
• W2359630417 hasConcept C535046627 @default.
• W2359630417 hasConcept C61367390 @default.
• W2359630417 hasConcept C71315377 @default.
• W2359630417 hasConcept C71924100 @default.
• W2359630417 hasConceptScore W2359630417C121608353 @default.
• W2359630417 hasConceptScore W2359630417C126322002 @default.
• W2359630417 hasConceptScore W2359630417C126894567 @default.
• W2359630417 hasConceptScore W2359630417C142724271 @default.
• W2359630417 hasConceptScore W2359630417C143998085 @default.
• W2359630417 hasConceptScore W2359630417C197934379 @default.
• W2359630417 hasConceptScore W2359630417C203092338 @default.
• W2359630417 hasConceptScore W2359630417C204787440 @default.
• W2359630417 hasConceptScore W2359630417C27081682 @default.
• W2359630417 hasConceptScore W2359630417C2776551883 @default.
• W2359630417 hasConceptScore W2359630417C2777899217 @default.
• W2359630417 hasConceptScore W2359630417C2778375690 @default.
• W2359630417 hasConceptScore W2359630417C2778575703 @default.
• W2359630417 hasConceptScore W2359630417C2778894405 @default.
• W2359630417 hasConceptScore W2359630417C2779279991 @default.
• W2359630417 hasConceptScore W2359630417C2779448150 @default.
• W2359630417 hasConceptScore W2359630417C2780192828 @default.
• W2359630417 hasConceptScore W2359630417C2780962315 @default.
• W2359630417 hasConceptScore W2359630417C2781190966 @default.
• W2359630417 hasConceptScore W2359630417C535046627 @default.
• W2359630417 hasConceptScore W2359630417C61367390 @default.
• W2359630417 hasConceptScore W2359630417C71315377 @default.
• W2359630417 hasConceptScore W2359630417C71924100 @default.
• W2359630417 hasIssue "6_suppl" @default.
• W2359630417 hasLocation W23596304171 @default.
• W2359630417 hasOpenAccess W2359630417 @default.
• W2359630417 hasPrimaryLocation W23596304171 @default.
• W2359630417 hasRelatedWork W2590294003 @default.
• W2359630417 hasRelatedWork W2770702948 @default.
• W2359630417 hasRelatedWork W2790343864 @default.
• W2359630417 hasRelatedWork W2921176969 @default.
• W2359630417 hasRelatedWork W3023947295 @default.
• W2359630417 hasRelatedWork W4205706045 @default.
• W2359630417 hasRelatedWork W4229076799 @default.
• W2359630417 hasRelatedWork W4255124575 @default.
• W2359630417 hasRelatedWork W4283759191 @default.
• W2359630417 hasRelatedWork W4295836975 @default.
• W2359630417 hasVolume "31" @default.
• W2359630417 isParatext "false" @default.
• W2359630417 isRetracted "false" @default.
• W2359630417 magId "2359630417" @default.

• next